Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: November 10, 2025
Principal Executive Office: Marseille, France
This filing serves as a cover document incorporating by reference a press release (Exhibit 99.1) dated November 10, 2025. The filing is intended to be incorporated into the company's registration statements on Form F-3 and Form S-8.
Key Financial Metrics
The provided filing text is a cover sheet and does not contain specific financial data. The following metrics are not present in the source text:
- Revenue: Not provided.
- Profit/Loss: Not provided.
- Cash Flow: Not provided.
- Margins: Not provided.
- Debt and Liquidity: Not provided.
Material Changes
The filing text does not disclose specific material changes in financial position or operations. It references a press release (Exhibit 99.1) which likely contains the substantive news, but the content of that release is not included in the provided input.
Guidance, Outlook, and Risks
Management Commentary: The filing explicitly excludes quotations from Jonathan Dickinson (CEO) and Sonia Quaratino (CMO) from the incorporation by reference into the registration statements, though these individuals are identified as signatories and officers.
Guidance and Risks: No specific guidance, outlook, risk factors, or contingencies are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 10, 2025) to obtain the actual news or data triggering this filing.
- Verify the specific content of the CEO and CMO quotations that were excluded from the registration statement incorporation.
- Check the referenced registration statements (Form F-3 File No. 333-276164 and Form S-8 File No. 333-282031) for updated prospectuses.
- Confirm if the press release contains clinical trial results, partnership announcements, or regulatory updates typical for a biopharmaceutical company.